Teva Pharmaceutical Industries (TEVA) Stock News, May 15-29, 2025

Teva Pharmaceutical (NYSE: TEVA) has received Fast Track designation from the FDA for TEV-53408, an anti-IL-15 antibody being developed for celiac disease treatment. The drug candidate is currently in Phase 2a trials evaluating its efficacy and safety in adult celiac patients on a gluten-free diet. TEV-53408 works by inhibiting interleukin-15 (IL-15) to prevent intestinal damage and associated symptoms. The Fast Track status highlights the treatment's potential and the significant unmet medical need in celiac disease, which affects approximately 1% of the global population. This development demonstrates Teva's commitment to expanding its innovative pipeline in immunological conditions.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced upcoming presentations by its executive management team at two major healthcare conferences in June 2025. At the Jefferies Global Healthcare Conference on June 4, EVP U.S. Commercial Chris Fox and EVP Global R&D and Chief Medical Officer Dr. Eric Hughes will present at 9:20 am ET. At the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, President & CEO Richard Francis will present at 8:00 am ET. Live webcasts will be available on Teva's Investor Relations website, with archived versions accessible within 24 hours after each presentation.

Teva Pharmaceutical and Biolojic Design have initiated IND-enabling studies for BD9, a novel dual-specific multibody targeting both TSLP and IL-13 for treating atopic dermatitis and asthma. BD9 was developed using Biolojic's Multibody Platform, which creates antibodies capable of addressing multiple disease targets simultaneously. The therapy aims to improve outcomes for patients with TH2-driven inflammatory diseases where current treatments are inadequate. This development aligns with Teva's Pivot to Growth strategy to enhance innovation in their pipeline. Under the agreement, Teva holds worldwide development rights for BD9, while Biolojic is eligible for milestone payments based on pre-clinical, clinical, regulatory, and commercial achievements.

Teva Pharmaceutical (NYSE: TEVA) has announced an increase in its debt tender offer from $2.0 billion to $2.25 billion. The company is also raising the Pool Tender Caps for Pool 2 Notes and Pool 3 Notes from $250 million to $350 million each. This follows Teva's successful pricing of approximately $2.3 billion in senior notes on May 20, 2025. The tender offer includes multiple series of notes with varying interest rates and maturities, structured in three pools. Pool 1 has a maximum amount of $1.55 billion, while Pool 2 and Pool 3 each have a cap of $350 million. The offer expires on June 17, 2025, with an Early Tender Time of June 2, 2025. Holders who tender by the Early Tender Time will receive the Total Consideration, which includes an Early Tender Premium.

Teva Pharmaceutical has successfully upsized and priced approximately $2.3 billion in senior notes, increased from the previously announced $2 billion. The notes consist of: €1 billion of 4.125% EUR-denominated notes maturing in 2031, $500 million of 6.000% USD-denominated notes maturing in 2032, and $700 million of 5.750% USD-denominated notes maturing in 2030. The proceeds will be used to fund tender offers for existing notes and repay outstanding debt. The settlement is expected around May 28, 2025. The notes will be unsecured senior obligations guaranteed by Teva and were offered through their shelf registration statement.

Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Fitch Ratings Agency to BB+ from BB, with a stable outlook. The upgrade follows a recent rating improvement from Moody's and reflects Teva's successful debt reduction efforts and improved financial flexibility. Fitch's report highlights expected revenue growth from key products AUSTEDO and AJOVY, along with the company's promising biosimilar pipeline. The agency also noted that Teva's focus on optimizing external spend, resource allocation, and organizational modernization is anticipated to boost operating margins.

Teva Pharmaceutical announced a $2 billion senior notes offering through its finance subsidiaries. The offering includes both EUR-denominated and USD-denominated notes. The company plans to use the proceeds, along with cash on hand, to fund tender offers for several existing senior notes due between 2026 and 2031, with a maximum combined purchase price of up to $2 billion. Any remaining proceeds will be used for repaying outstanding debt. The notes will be unsecured senior obligations of the issuers and will be unconditionally guaranteed by Teva. The offering will be made through Teva's automatic shelf registration statement on Form S-3, filed with the SEC on February 7, 2025.

Teva Pharmaceutical (NYSE: TEVA) has launched tender offers to purchase up to $2 billion worth of senior notes due between 2026-2031. The tender offers cover six series of notes issued by Teva's finance subsidiaries and guaranteed by Teva, including both USD and EUR denominated securities. The offers are structured in three pools with specific caps: Pool 1 ($1.55B max), Pool 2 ($250M equivalent max), and Pool 3 ($200M equivalent max). Holders tendering by June 2, 2025 (Early Tender Time) will receive the Total Consideration including a $50/€50 premium per $1,000/€1,000 principal amount. The offers expire on June 17, 2025. Teva plans to fund these purchases through a new debt offering and cash on hand, aiming to proactively manage its debt structure and extend its maturity profile.

Teva Pharmaceuticals (TEVA) has received a credit rating upgrade from Moody's Investor Services, raising the company's corporate credit rating to Ba1 with a stable outlook from Ba2 with a positive outlook. The upgrade reflects Teva's significant global presence, growth in branded franchises, stabilization of its generics business, and successful debt reduction efforts. According to CFO Eli Kalif, this upgrade validates the success of Teva's Pivot to Growth strategy and is expected to result in improved debt costs and broader access to investors.